These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 15073851

  • 1. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 2. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H, Okamura K, Takashi M, Shimoji T, Miyake K.
    Hinyokika Kiyo; 1997 Feb 15; 43(2):89-96. PubMed ID: 9086342
    [Abstract] [Full Text] [Related]

  • 3. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S, Nakano M, Matsuzaki M, Watanabe J, Morikawa H, Murata H, Oda H, Komatsu H.
    Hinyokika Kiyo; 2005 Mar 15; 51(3):155-8. PubMed ID: 15852667
    [Abstract] [Full Text] [Related]

  • 4. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct 15; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

  • 5. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
    Bellmunt Molins J, Ribas A, Albanell J, Lorente Garín JA, de Torres Mateos JA, Morote Robles J, López Palacios MA, Banús Gassol JM, Casado Cobo S, Eres N, Solé Calvo LA.
    Arch Esp Urol; 1996 Jun 15; 49(5):465-72. PubMed ID: 8766083
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED.
    Cancer; 2005 Oct 15; 104(8):1627-32. PubMed ID: 16138364
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    J Urol; 1995 Jan 15; 153(1):47-52. PubMed ID: 7966789
    [Abstract] [Full Text] [Related]

  • 8. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Sep 15; 14(9):828-32. PubMed ID: 17760750
    [Abstract] [Full Text] [Related]

  • 10. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N, Kosmas C, Skopelitis H, Dimitrakopoulos A, Kopterides P, Bougas D, Stravodimos K, Mitropoulos D, Alamanis C, Giannopoulos A.
    J Chemother; 2005 Aug 15; 17(4):441-8. PubMed ID: 16167525
    [Abstract] [Full Text] [Related]

  • 11. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.
    Hinyokika Kiyo; 1988 Aug 15; 34(8):1371-5. PubMed ID: 3195405
    [Abstract] [Full Text] [Related]

  • 12. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, Fujimoto H, Fujiwara Y.
    Eur Urol; 2007 Oct 15; 52(4):1115-22. PubMed ID: 17433855
    [Abstract] [Full Text] [Related]

  • 13. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun 15; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

  • 14. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E, AGO-OVAR, GINECO.
    J Natl Cancer Inst; 2006 Aug 02; 98(15):1036-45. PubMed ID: 16882940
    [Abstract] [Full Text] [Related]

  • 15. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA.
    J Natl Cancer Inst; 2010 Oct 20; 102(20):1547-56. PubMed ID: 20937992
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
    Johannsen M, Sachs M, Roigas J, Hinke A, Staack A, Loening SA, Schnorr D, Wille AH.
    Eur Urol; 2005 Aug 20; 48(2):246-51. PubMed ID: 15963636
    [Abstract] [Full Text] [Related]

  • 17. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A.
    J Clin Oncol; 2010 Jul 10; 28(20):3323-9. PubMed ID: 20498395
    [Abstract] [Full Text] [Related]

  • 18. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2008 Sep 10; 61(3):369-77. PubMed ID: 18308419
    [Abstract] [Full Text] [Related]

  • 19. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
    Yamada Y, Itoh Y, Aoki S, Nakamura K, Taki T, Naruse K, Tobiume M, Zennami K, Katsuda R, Kato Y, Watanabe M, Nishikawa G, Minami M, Nakahira M, Ukai S, Sawada M, Kitamura A, Honda N.
    Cancer Chemother Pharmacol; 2009 Nov 10; 64(6):1079-83. PubMed ID: 19277660
    [Abstract] [Full Text] [Related]

  • 20. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, De Paula F, Scarpone P, De Carli P, Pizzo M, Platania A, Amini M.
    Cancer; 2003 Apr 01; 97(7):1644-52. PubMed ID: 12655521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.